Genentech
Overview
flowchart TD
companies_genentech["Genentech Inc."]
style companies_genentech fill:#4fc3f7,stroke:#333,color:#000
companies_genentech_0["Company Overview"]
companies_genentech -->|"includes"| companies_genentech_0
style companies_genentech_0 fill:#81c784,stroke:#333,color:#000
companies_genentech_1["Alzheimers Disease Programs"]
companies_genentech -->|"includes"| companies_genentech_1
style companies_genentech_1 fill:#ef5350,stroke:#333,color:#000
companies_genentech_2["Crenezumab"]
companies_genentech -->|"includes"| companies_genentech_2
style companies_genentech_2 fill:#ffd54f,stroke:#333,color:#000
companies_genentech_3["Gantenerumab"]
companies_genentech -->|"includes"| companies_genentech_3
style companies_genentech_3 fill:#ce93d8,stroke:#333,color:#000
companies_genentech_4["LRRK2 Inhibitor Program"]
companies_genentech -->|"includes"| companies_genentech_4
style companies_genentech_4 fill:#4fc3f7,stroke:#333,color:#000
companies_genentech_5["Other Programs"]
companies_genentech -->|"includes"| companies_genentech_5
style companies_genentech_5 fill:#81c784,stroke:#333,color:#000
...Genentech
Overview
Mermaid diagram (expand to render)
Genentech is a US biotechnology company and subsidiary of Roche, focused on neuroscience research and drug development. Founded in 1976 in South San Francisco, California, Genentech pioneered the recombinant DNA technology era and has become one of the world's leading biotechnology companies. Since its acquisition by Roche in 2009 for approximately 7 billion, Genentech operates as an independent subsidiary while leveraging Roche's global resources and pipeline infrastructure["@genentech"].
Company Overview
| Attribute | Value |
|-----------|-------|
| Parent Company | Roche |
| Founded | 1976 |
| Headquarters | South San Francisco, CA |
| CEO | Thomas Schinecker |
| Employees | ~13,000 |
| Revenue (2023) | ~$7.5 billion |
Alzheimer's Disease Programs
Genentech has a long history in Alzheimer's disease research, with multiple programs targeting amyloid-beta and tau pathology. Their neuroscience division focuses on understanding disease mechanisms and developing disease-modifying therapies[@roche].
Crenezumab
Crenezumab is an anti-amyloid-beta monoclonal antibody developed in partnership with AC Immune. Unlike other anti-Aβ antibodies, crenezumab targets both monomers and oligomers of Aβ, potentially providing broader pathological coverage[@cread2019].
- Mechanism: Monoclonal antibody targeting Aβ monomers and oligomers
- Target: Amyloid-beta aggregates
- Phase: Failed Phase 3 (CREAD trials)
- Development History: Originally developed by AC Immune, licensed to Genentech/Roche in 2006
- Trial Results: The CREAD and CREAD2 Phase 3 trials in early AD patients failed to meet primary endpoints (ADAS-Cog13) in 2019. The antibody showed lower than expected brain amyloid reduction
- Key Publications:
- [Lacour et al., Nature (2017)](https://doi.org/10.1038/nature24023)
- [CREAD Phase 3 Results (2019)](https://doi.org/10.1002/alz.019)
Gantenerumab
Gantenerumab is a fully human monoclonal antibody that binds to Aβ plaques and promotes their removal via [microglia](/cell-types/microglia-neuroinflammation)-mediated phagocytosis[@gantenerumab2023].
- Mechanism: Anti-Aβ antibody with plaque-binding and Fc receptor engagement
- Target: Amyloid plaques
- Phase: Withdrawn (previously Phase 3)
- Development History: Co-developed with Roche; discontinued after GRADUATE trials
- Trial Results: The GRADUATE program (GRADUATE-1 and GRADUATE-2) failed to meet primary endpoints in 2022. Despite significant amyloid reduction (up to 57% in some patients), no clinical benefit was observed
- Key Publications: [Ostrowitzki et al., Nature (2012)](https://doi.org/10.1038/nature11476)
LRRK2 Inhibitor Program
Genentech and Roche have an active preclinical LRRK2 inhibitor program in collaboration with Vanqua Bio. The lead compound from this partnership is G007-LK, a potent, selective, and brain-penetrant small molecule LRRK2 kinase inhibitor.
| Attribute | Value |
|-----------|-------|
| Lead Compound | G007-LK |
| Target | LRRK2 (leucine-rich repeat kinase 2) |
| Indication | Parkinson's disease (LRRK2 mutation carriers) |
| Stage | Preclinical / IND-enabling |
| Route | Oral |
| Collaboration | Vanqua Bio (joint development) |
G007-LK Design:
- High potency (low nanomolar IC50 for LRRK2)
- >100-fold selectivity over related kinases
- Brain-to-plasma ratio >1.0 (favorable CNS exposure)
- Once-daily oral dosing
- ATP-competitive inhibitor of LRRK2 kinase domain
Preclinical Profile:
- Dose-dependent pSer935-LRRK2 reduction in brain and peripheral tissues (validated biomarker)
- Normalized Rab10 and Rab8 phosphorylation
- Enhanced autophagic flux in LRRK2 G2019S knock-in mice
- Improved motor coordination in disease models
- Favorable safety in non-human primates at projected human doses
G007-LK competes in the LRRK2 inhibitor landscape alongside BIIB122 (Biogen/Denali, Phase 2b) and NEU-411 (Neuron23, Phase 2). The collaboration with Vanqua Bio provides Genentech with a differentiated, highly selective LRRK2 inhibitor for the treatment of Parkinson's disease[@g007lk_jmc].
For more detail, see [G007-LK LRRK2 Inhibitor](/therapeutics/g007-lk-lrrk2-inhibitor).
Other Programs
Genentech's neuroscience pipeline includes earlier-stage programs targeting:
- [Tau](/proteins/tau) pathology (anti-tau antibodies)
- [Microglia](/cell-types/microglia)l modulation (CSF1R inhibitors)
- Synaptic plasticity and function
- [Neurodegeneration](/diseases/neurodegeneration) biomarkers
Partnership and Licensing
AC Immune Collaboration
Genentech maintains a strategic partnership with AC Immune SA for the development of anti-amyloid and anti-tau therapeutics. This collaboration has generated multiple clinical candidates including crenezumab and ACI-35 (tau vaccine)[@immune].
Roche Neuroscience Pipeline
As part of Roche's broader neuroscience efforts, Genentech contributes to:
- Shared clinical trial infrastructure
- Biomarker development
- Patient recruitment for Phase 2/3 studies
- Regulatory strategy for CNS drugs
Research Focus Areas
Amyloid Hypothesis
Genentech has been a strong proponent of the amyloid cascade hypothesis, believing that early intervention with amyloid-targeting therapies may prevent or slow disease progression. Their clinical trial programs have helped advance understanding of:
- [Amyloid](/mechanisms/amyloid-aggregation) PET imaging biomarkers
- Disease staging using CSF biomarkers
- Clinical outcome measures in early AD
Tau Research
Beyond amyloid, Genentech investigates tau protein pathology as a key driver of neurodegeneration. Tau-targeted programs include:
- Anti-tau antibodies
- [Tau](/proteins/tau) aggregation inhibitors
- [Tau](/proteins/tau) PET tracers (in collaboration with Roche)
Related Pages
- [AD Pipeline Companies](/companies/ad-pipeline-companies)
- [Roche](/companies/roche)
- [AC Immune](/companies/ac-immune)
- [Alzheimer's Disease](/diseases/alzheimers-disease)
- [Amyloid Beta](/proteins/amyloid-beta)
- [Tau Protein](/proteins/tau)
See Also
- [Alzheimer's Disease](/diseases/alzheimers-disease)
- [Parkinson's Disease](/diseases/parkinsons-disease)
- [Biomarkers](/biomarkers/alzheimers-biomarkers)
References
Unknown, Genentech Corporate Website (n.d.)
Unknown, Roche Neuroscience Pipeline (n.d.)
[Unknown, CREAD Trial - Alzheimer's & Dementia (2019) (2019)](https://doi.org/10.1016/j.jalz.2019.06.4953)
[Unknown, Gantenerumab GRADUATE Trials - Nature (2023) (2023)](https://doi.org/10.1038/s41591-023-02361-0)
Unknown, AC Immune Partnership (n.d.)